RaQualia Pharma Inc.

4579

JP3967150008

Pharmaceuticals

Delayed Japan Exchange Other stock markets 10:30:00 2024-04-30 pm EDT			5-day change	1st Jan Change
591 ^JPY	-0.67%		-2.96%	-14.10%

Mar. 26	RaQualia Pharma Inc. completed the acquisition of FIMECS, Inc. from Yusuke Tominari, Kamakanae, Nissay Capital No. 11 Investment Limited Partnership managed by Nissay Capital Co., Ltd., ANRI No. 4 Fund managed by ANRI and others.	CI
Feb. 14	RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2024	CI

RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2024

February 14, 2024 at 02:30 am EST

RaQualia Pharma Inc. provided consolidated earnings guidance for the year ending December 31, 2024. For the year, the company expects net sales of JPY 4,535 million, operating profit of JPY 313 million and profit attributable to owners of parent of JPY 236 million or JPY 10.91 per basic share.

Latest news about RaQualia Pharma Inc.

RaQualia Pharma Inc. completed the acquisition of FIMECS, Inc. from Yusuke Tominari, Kamakanae, Nissay Capital No. 11 Investment Limited Partnership managed by Nissay Capital Co., Ltd., ANRI No. 4 Fund managed by ANRI and others.	Mar. 25	CI
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2024	Feb. 14	CI
RaQualia Pharma Inc. agreed to acquire FIMECS, Inc. from Nissay Capital No. 11 Investment Limited Partnership and Nissay Capital Co., Ltd. for ¥4.5 billion.	Feb. 13	CI
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023	23-08-10	CI
RaQualia Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023	23-05-15	CI
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	23-02-14	CI
RaQualia Pharma Inc. announced that it has received ¥805.6125 million in funding from CVI Investments, Inc.	23-01-04	CI
RaQualia Pharma Inc. announced that it expects to receive Ã‘805.6125 million in funding from CVI Investments, Inc.	22-12-19	CI
Raqualia Pharma Inc. Provides Consolidated Earnings Guidance for Year Ending December 31, 2022	22-11-11	CI
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022	22-08-15	CI
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022	22-02-15	CI
RaQualia Pharma Inc. Provides Earnings Guidance for the Year Ending December 31, 2021	21-11-12	CI
Raqualia Pharma Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2021	21-08-12	CI
RaQualia Pharma Inc. Announces Consolidated Financial Results for the Six Months Ended June 30, 2021	21-08-12	CI
RaQualia Pharma Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2021	21-05-14	CI
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021	21-05-14	CI
Yuichi Kakinuma Withdraws Shareholder Proposal to RaQualia Pharma	21-05-06	CI
RaQualia Pharma Inc. Provides Earnings Guidance for the Year Ending December 31, 2021	21-02-12	CI
RaQualia Pharma Inc. Announces Consolidated Earnings Results for the Year Ended December 31, 2020	21-02-12	CI
RaQualia Pharma Inc. Announces Consolidated Financial Results for the Nine Months Ended September 30, 2020	20-11-13	CI
RaQualia Pharma Inc. Provides Financial Guidance for the Fiscal Year Ending December 31, 2020	20-11-13	CI
Yuichi Kakinuma Submits Shareholder Proposal to RaQualia Pharma	20-09-02	CI
RaQualia Pharma Inc. Revises Earnings Guidance for the Full Year Ended December 31, 2020	20-08-14	CI
RaQualia Pharma Inc. Announces Consolidated Financial Results for the Six Months Ended June 30, 2020	20-08-14	CI

Chart RaQualia Pharma Inc.

Duration

Period

More charts

Company Profile

RaQualia Pharma Inc. is a Japan-based company engaged in the research and development of pharmaceutical products. The Company is mainly engaged in the discovery and research, the preclinical trials and part of clinical trials of drugs, as well as the licensing of developed compounds to pharmaceutical companies. The Company is focused on pain diseases area and intestinal disease area. Its products include EP4 antagonist, cyclooxygenase-2 (COX-2) inhibitory, 5-HT4 portion partial agonist, among others.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

595 JPY

Average target price

1,800 JPY

Spread / Average Target

+202.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
RAQUALIA PHARMA INC.	-14.10%	82.11M
ELI LILLY AND COMPANY	+34.00%	664B
NOVO NORDISK A/S	+29.29%	567B
JOHNSON & JOHNSON	-7.75%	354B
MERCK & CO., INC.	+18.53%	330B
ABBVIE INC.	+4.95%	286B
ASTRAZENECA PLC	+13.79%	234B
NOVARTIS AG	+4.93%	199B
ROCHE HOLDING AG	-9.78%	196B
AMGEN INC.	-4.89%	148B

Other Pharmaceuticals